Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 5/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912027 | 0.75 | MPO (0.33) | HTR5A | |
| SCHEMBL884890 | 0.75 | KDM1A (0.39) | HTR7 | |
| SCHEMBL886112 | 0.72 | MAPK1 (0.38) | — | |
| SCHEMBL4284969 | 0.65 | TAAR1 (0.35) | TAAR1HTR5ACRHBPCRHR2TSHR | |
| SCHEMBL4278345 | 0.64 | MAOA (0.37) | — | |
| SCHEMBL4238081 | 0.63 | BACE1 (0.59) | TAAR1HTR5ACRHBPCRHR2TSHR | |
| SCHEMBL5067771 | 0.63 | TAAR1 (0.43) | TAAR1HTR5ATSHRHTR1AHTR1D | |
| SCHEMBL14656047 | 0.62 | TAAR1 (0.35) | TAAR1HTR5ACRHBPCRHR2HTR1A | |
| SCHEMBL3984810 | 0.62 | L3MBTL1 (0.40) | — | |
| SCHEMBL1604324 | 0.59 | HDAC4 (0.43) | TAAR1TSHRHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | TAAR1 3403/4885HTR5A 3611/4885CRHBP 4556/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | TAAR1 3045/4885HTR5A 3618/4885CRHBP 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.